Media ReleasesInnate Immunotherapeutics

View All Innate Immunotherapeutics News

Innate Immunotherapeutics, Gordon Capital Research Update



On April 20, Innate Immunotherapeutics announced the last study-related clinical visit by patients suffering from Secondary Progressive Multiple Sclerosis (SPMS) and participating in the Phase 2B clinical trial of MIS416 had been completed.

The trial was designed to determine the efficacy of MIS416 using a variety of tests for neuromuscular function.

Following the completion of the clinical phase of the study, the Company will now begin detailed data entry, analysis and compilation of all patient-generated data from each participant who completed all 61 scheduled visits over the 12-month trial period with each generating approximately 400 pages of data.

To view Update please download PDF attached:
Download this document